| Balance sheet (USD) | FY 2026 ended Jun 30, 2026 | FY 2025 ended Jun 30, 2025 | FY 2024 ended Jun 30, 2024 | FY 2023 ended Jun 30, 2023 | FY 2022 ended Jun 30, 2022 | FY 2021 ended Jun 30, 2021 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 832.0K | 12.1K | 21.1K | 10.0K | 4.1K | 2.3K |
| Total current assets | 8.54M | 8.35M | 25.4K | 19.0K | 15.0K | 6.6K |
| Property, plant and equipment | 3.9K | 302 | 2.0K | 4.3K | ||
| Total assets | 12.78M | 19.63M | 72.4K | 60.3K | 81.7K | 13.1K |
| Accounts payable | 1.13M | 1.25M | 1.21M | 966.7K | 943.0K | 1.00M |
| Total current liabilities | 3.35M | 5.58M | 3.79M | 3.16M | 3.06M | 3.08M |
| Long-term debt | 537.9K | 399.3K | 390.5K | 926.4K | 624.6K | |
| Total liabilities | 3.38M | 5.73M | 3.85M | 3.18M | 3.11M | 3.08M |
| Retained earnings | -144.48M | -125.62M | -66.70M | -64.68M | -61.56M | -58.20M |
| Shareholders' equity | 9.40M | 13.91M | -3.78M | -3.12M | -3.02M | -3.07M |
| Total debt | 537.9K | 399.3K | 390.5K | 926.4K | 624.6K | |
| Net debt | 525.8K | 378.2K | 380.5K | 922.4K | 622.3K |
From Propanc Biopharma, Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.